Table 3.
Individual clinical components that were used to separate patients based on subcortical ischaemic vascular disease scores (BDS)
| Adjusted BDS
|
p Value | ||
|---|---|---|---|
| <6 (n=24) | ≥6 (n=28) | ||
| Hypertension* | 8, 33% | 20, 71% | 0.006 |
| Diabetes mellitus* | 3, 13% | 9, 32% | 0.09 |
| Abnormal reflexes* | 13, 54% | 9, 32% | 0.03 |
| Abnormal gait* | 10, 42% | 25, 89% | <0.001 |
| Executive T score† | 46.27 (1.50) | 40.78 (1.51) | 0.01 |
| N-acetylaspartate† | 11.75 (0.41) | 10.86 (0.30) | 0.076 |
| Choline† | 1.97 (0.07) | 1.81 (0.06) | 0.08 |
| Creatine† | 6.94 (0.17) | 6.48 (0.17) | 0.06 |
| Albumin ratio† | 5.44 (0.63) | 7.64 (0.48) | 0.009 |
| BBB permeability (Ki)† | 0.0020 (0.0002) | 0.0031 (0.0010) | 0.29 |
| MMP-2 index† | 0.015 (0.002) | 0.008 (0.001) | 0.009 |
| MMP-9 index† | 0.0020 (0.0014) | 0.0011 (0.0003) | 0.43 |
| Aβ1–42/log(P-τ181)† | 150.60 (24.47) | 159.11 (14.27) | 0.75 |
Those with few components positive had low scores (<6), while those with high scores (≥6) corresponded to patients with BD.
*
(n, %).
†
(Mean (SEM)).
Aβ42, amyloid-β1–42; BBB, blood-brain barrier; BDS, Binswanger disease score; MMP, matrix metalloproteinase; P-τ181, phosphorylated-τ181.